FibroBiologics Inc. (NASDAQ:FBLG) on Wednesday announced that it has enrolled and dosed the first patients in its Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).
FibroBiologics Does First Patients In CYWC628 Trial
Something went wrong.
FibroBiologics said it has dosed the first patients in the CYWC628 Phase 1/2 clinical trial.
The CYWC628 fibroblast-based therapy targets diabetic foot ulcers, a condition that affects millions of patients worldwide and currently lacks effective long-term treatment solutions.
